BET-BAY 002BET inhibitor, potent CAS# 1588521-78-1 |
- Bestatin trifluoroacetate
Catalog No.:BCC3909
CAS No.:223763-80-2
- Fumagillin
Catalog No.:BCC2347
CAS No.:23110-15-8
- Tosedostat (CHR2797)
Catalog No.:BCC2309
CAS No.:238750-77-1
- Bestatin hydrochloride
Catalog No.:BCC3908
CAS No.:65391-42-6
- Alogliptin (SYR-322)
Catalog No.:BCC2113
CAS No.:850649-61-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1588521-78-1 | SDF | Download SDF |
| PubChem ID | 73425805 | Appearance | Powder |
| Formula | C22H18ClN5O | M.Wt | 403.86 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (123.81 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[[(4R)-6-(4-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1]benzazepin-4-yl]methyl]-5-methyl-1,3,4-oxadiazole | ||
| SMILES | CC1=NN=C2N1C3=CC=CC=C3C(=CC2CC4=NN=C(O4)C)C5=CC=C(C=C5)Cl | ||
| Standard InChIKey | AGYIAWHWIUZNSD-INIZCTEOSA-N | ||
| Standard InChI | InChI=1S/C22H18ClN5O/c1-13-24-27-22-16(12-21-26-25-14(2)29-21)11-19(15-7-9-17(23)10-8-15)18-5-3-4-6-20(18)28(13)22/h3-11,16H,12H2,1-2H3/t16-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
BET-BAY 002 Dilution Calculator
BET-BAY 002 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4761 mL | 12.3805 mL | 24.7611 mL | 49.5221 mL | 61.9026 mL |
| 5 mM | 0.4952 mL | 2.4761 mL | 4.9522 mL | 9.9044 mL | 12.3805 mL |
| 10 mM | 0.2476 mL | 1.2381 mL | 2.4761 mL | 4.9522 mL | 6.1903 mL |
| 50 mM | 0.0495 mL | 0.2476 mL | 0.4952 mL | 0.9904 mL | 1.2381 mL |
| 100 mM | 0.0248 mL | 0.1238 mL | 0.2476 mL | 0.4952 mL | 0.619 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.
- ent-17-Hydroxykaura-9(11),15-dien-19-oic acid
Catalog No.:BCN6788
CAS No.:1588516-88-4
- 3Alaph-Tigloyloxypterokaurene L3
Catalog No.:BCN6787
CAS No.:1588516-87-3
- Boc-ß-HoAla-OH
Catalog No.:BCC3224
CAS No.:158851-30-0
- 3-O-(2'E ,4'Z-decadienoyl)-20-O-acetylingenol
Catalog No.:BCN1550
CAS No.:158850-76-1
- GR 159897
Catalog No.:BCC7001
CAS No.:158848-32-9
- Escin IIB
Catalog No.:BCN8127
CAS No.:158800-83-0
- Salvianolic acid F
Catalog No.:BCN2924
CAS No.:158732-59-3
- Aescin IIA
Catalog No.:BCN6551
CAS No.:158732-55-9
- 2-Naphthyl N-benzoylphenylalaninate
Catalog No.:BCC8583
CAS No.:15873-25-3
- Dihydrexidine hydrochloride
Catalog No.:BCC5681
CAS No.:158704-02-0
- Rimonabant hydrochloride
Catalog No.:BCC1898
CAS No.:158681-13-1
- Ombuin 3-glucoside
Catalog No.:BCN4055
CAS No.:158642-42-3
- GR 231118
Catalog No.:BCC7085
CAS No.:158859-98-4
- APC 366
Catalog No.:BCC7392
CAS No.:158921-85-8
- Boc-D-Tryptophanol
Catalog No.:BCC2698
CAS No.:158932-00-4
- Secoisolarisiresinol Diglucoside
Catalog No.:BCC9140
CAS No.:158932-33-3
- Wedelobatin A
Catalog No.:BCN6731
CAS No.:1589488-34-5
- Wedelobatin B
Catalog No.:BCN6730
CAS No.:1589488-35-6
- 6-Benzyloxyindole
Catalog No.:BCC8769
CAS No.:15903-94-3
- F1839-I
Catalog No.:BCN6450
CAS No.:159096-49-8
- 3F8
Catalog No.:BCC6112
CAS No.:159109-11-2
- CARIPORIDE
Catalog No.:BCC6432
CAS No.:159138-80-4
- L-755,507
Catalog No.:BCC7282
CAS No.:159182-43-1
- MM 77 dihydrochloride
Catalog No.:BCC6854
CAS No.:159187-70-9
Corrigendum: Orf Virus 002 Protein Targets Ovine Protein S100A4 and Inhibits NF-kappaB Signaling.[Pubmed:28179903]
Front Microbiol. 2017 Feb 7;8:160.
[This corrects the article on p. 1389 in vol. 7, PMID: 27679610.].
Safety and efficacy of intramuscular human placenta-derived mesenchymal stromal-like cells (cenplacel [PDA-002]) in patients who have a diabetic foot ulcer with peripheral arterial disease.[Pubmed:28133924]
Int Wound J. 2017 Oct;14(5):823-829.
The objective of this study was to examine the safety of cenplacel (PDA-002) in patients with peripheral arterial disease (PAD) and a diabetic foot ulcer (DFU). Cenplacel is a mesenchymal-like cell population derived from full-term human placenta. This phase 1, dose-escalation study investigated cenplacel in diabetic patients with chronic DFUs (Wagner grade 1 or grade 2) and PAD [ankle-brachial index (ABI) >0.5 and /=6 months and 11 had an ABI of 0.7-0.85. No patient met dose-limiting toxicity criteria and no treatment-related serious adverse events were reported. There was preliminary evidence of ulcer healing in seven patients (five complete; two partial) within 3 months of cenplacel treatment, and circulating endothelial cell levels (a biomarker of vascular injury in PAD) were decreased within 1 month. Cenplacel was generally safe and well tolerated in patients with chronic DFUs and PAD. Outcomes from this study informed the doses, endpoints, biomarkers and patient population for an ongoing phase 2 trial.
Early management of sepsis with emphasis on early goal directed therapy: AME evidence series 002.[Pubmed:28275488]
J Thorac Dis. 2017 Feb;9(2):392-405.
Severe sepsis and septic shock are major causes of morbidity and mortality in patients entering the emergency department (ED) or intensive care unit (ICU). Despite substantial efforts to improve patient outcome, treatment of sepsis remains challenging to clinicians. In this context, early goal directed therapy (EGDT) represents an important concept emphasizing both early recognition of sepsis and prompt initiation of a structured treatment algorithm. As part of the AME evidence series on sepsis, we conducted a systematic review of all randomized controlled EGDT trials. Focus was laid on the setting (emergency department versus ICU) where EGDT was carried out. Early recognition of sepsis, through clinical or automated systems for early alert, together with well-timed initiation of the recommended therapy bundles may improve patients' outcome. However, the original "EGDT" protocol by Rivers and coworkers has been largely modified in subsequent trials. Currently, many investigators opt for an "expanded" EGDT (as suggested by the Surviving Sepsis Campaign). Evidence is also presented on the effectiveness of automated systems for early sepsis alert. Early recognition of sepsis and well-timed initiation of the SSC bundle may improve patient outcome.
Alcohol dependence and risk of somatic diseases and mortality: a cohort study in 19 002 men and women attending alcohol treatment.[Pubmed:28225200]
Addiction. 2017 Aug;112(8):1358-1366.
AIMS: To (1) estimate sex-specific risks of a comprehensive spectrum of somatic diseases in alcohol-dependent individuals versus a control population, and in the same population to (2) estimate sex-specific risks of dying from the examined somatic diseases. DESIGN: Register-based matched cohort study. Alcohol-dependent individuals were identified from the Copenhagen Alcohol Cohort. Controls were selected randomly from the Danish Civil Registration System. Information on somatic diseases was obtained from the Danish National Patient Registry and causes of death obtained from the Cause of Death Registry. Cox proportional hazards model was applied to estimate hazard ratios (HRs). SETTING: Denmark. PARTICIPANTS: A total of 19 002 alcohol-dependent individuals and 186 767 controls. MEASUREMENTS: Outcome variables included 11 disease groups and 29 subgroups, defined according to the International Classification of Diseases (ICD). The main predictor variable was diagnosis of alcohol dependence according to ICD. FINDINGS: Alcohol-dependent men and women compared with controls had statistically significantly higher risks of all disease groups and the majority of subgroups when analysed as disease events. HRs were elevated for well-established alcohol-related diseases but also for diseases such as dementia [men, HR = 2.0, 95% confidence interval (CI) = 1.6-2.3; women, HR = 2.4, 95% CI = 1.8-3.2], psoriasis (men, HR = 4.3, 95% CI = 3.5-5.2; women, HR = 5.4, 95% CI = 3.7-7.8) and breast cancer in men (HR = 3.3, 95% CI = 1.6-7.0). Similar results were found when disease groups and subgroups were analysed as causes of death. CONCLUSIONS: Alcohol-dependent men and women have significantly higher risks of a comprehensive spectrum of somatic diseases, both as disease events and as causes of death, relative to individuals from the general population.
